Wallace Owen B. 4
4 · Fulcrum Therapeutics, Inc. · Filed Jun 1, 2020
Insider Transaction Report
Form 4
Wallace Owen B.
Chief Scientific Officer
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2020-05-28−2,232→ 85,034 totalExercise: $7.84Exp: 2029-01-21→ Common Stock (2,232 underlying) - Exercise/Conversion
Common Stock
2020-05-28$7.84/sh+2,232$17,499→ 129,320 total - Sale
Common Stock
2020-05-28$20.00/sh−2,232$44,640→ 127,088 total
Footnotes (2)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019.
- [F2]The shares underlying the option are scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022.